LSD (lysergic acid diethylamide), first synthesized in 1938, is an extremely potent hallucinogen. Hallucinations are when you see, hear, feel, taste, or smell something that seems real but is not. It is commonly called Acid. LSD is synthetically made from lysergic acid, which is found in ergot, a fungus that grows on rye and other grains.

Lysergic acid diethylamide, commonly known as LSD (from German Lysergsäure-diethylamid), is a potent psychedelic drug that intensifies thoughts, emotions, and sensory perception. [11] .

Nonalcoholic fatty liver disease (NAFLD) will now be metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD encompasses patients who have hepatic steatosis and have at least one of five cardiometabolic risk factors.

Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease

2024年5月2日 · SIGNIFICANCE STATEMENT: Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, is the most prevalent chronic liver condition, affecting more than one-fourth of the global population.

2024年7月1日 · With resmetirom as the pioneering drug, an expanding pipeline of pharmacotherapies, including repurposed drugs and personalized medicine approaches, holds promise for effective management of SLD. Through interdisciplinary collaboration and coordinated action plans, we can address SLD as a systemic disease affecting multiple organs, striving for ...

2024年12月5日 · We introduce the ‘SLD burden paradox’: a concept illustrating the disparity in which metabolic dysfunction-associated steatotic liver disease is more prevalent, yet individuals with SLD and...

The American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction-associated steatotic liver disease (MASLD). To review the historical development leading to the changes and to discuss the implications of the changes on research and clinical practice.

2023年10月6日 · Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis, is the most prevalent chronic liver condition, affecting more than one-fourth of the global population.

Lysergic acid diethylamide (LSD) is a potent hallucinogen that has a high potential for abuse and currently has no accepted medical use in treatment in the United States.